Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Orion gains access to Glykos’ proprietary ADC technologies, initiating an ADC program and will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024